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asthma: a systematic overview of systematic 
reviews
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Antonella Muraro8, Graham Roberts9,10,11, Cezmi Akdis12, Matteo Bonini13, Ozlem Cavkaytar14, Breda Flood15, 
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Abstract 
Background: There is clinical uncertainty about the effectiveness and safety of allergen immunotherapy (AIT) for the 
treatment of allergic asthma.
Objectives: To undertake a systematic overview of the effectiveness, cost-effectiveness and safety of AIT for the 
treatment of allergic asthma.
Methods: We searched nine electronic databases from inception to October 31, 2015. Systematic reviews were inde-
pendently screened by two reviewers against pre-defined eligibility criteria and critically appraised using the Critical 
Appraisal Skills Programme quality assessment tool for systematic reviews. Data were descriptively and thematically 
synthesized.
Results: We identified nine eligible systematic reviews; these focused on delivery of AIT through the following routes: 
subcutaneous (SCIT; n = 3); sublingual (SLIT; n = 4); and both SCIT and SLIT (n = 2). This evidence found that AIT deliv-
ered by SCIT and SLIT can improve medication and symptom scores and measures of bronchial hyper-reactivity. The 
impact on measures of lung function or asthma control was however less clear. We found no systematic review level 
evidence on the cost-effectiveness of SCIT or SLIT. SLIT had a favorable safety profile when compared to SCIT, particu-
larly in relation to the risk of systemic reactions.
Conclusions: AIT has the potential to achieve reductions in symptom and medication scores, but there is no clear or 
consistent evidence that measures of lung function can be improved. Bearing in mind the limitations of synthesizing 
evidence from systematic reviews and the fact that these reviews include mainly dated studies, a systematic review 
of current primary studies is now needed to update this evidence base, estimate the effectiveness of AIT on asthma 
outcomes and to investigate the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT.
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Introduction
Asthma is a major public health problem affecting over 
300 million people worldwide [1]. Its prevalence and 
impact are particularly on the rise in urbanized regions. 
With a projected surge in the world’s urban population 
it is estimated that by 2025 an additional 100 million 
people may develop asthma [2]. Asthma is therefore set 
to become one of the world’s most prevalent chronic 
diseases.
Patho-physiologically, asthma is a chronic inflam-
matory disorder of the airways leading to airflow limi-
tation and remodelling [3]. The resulting signs and 
symptoms are dyspnea, cough, chest discomfort and 
wheezing. Based on clinical and laboratory findings, 
different asthma phenotypes have been described 
[4]. This review focuses on allergic asthma. Allergic 
asthma is one of the best described asthma phenotypes. 
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Allergic sensitization is a strong risk factor for asthma 
inception and severity in children and in adults [5]. 
Currently, there is no cure for asthma, but symptomatic 
control can be achieved in the majority of patients 
through a combination of short-acting bronchodilators 
and inhaled corticosteroids with minimal, if any, side-
effects. Long-acting beta-2 agonists, anti-leukotrienes, 
anticholinergics, theophylline, anti-IgE antibodies and 
other biologic agents can be added to achieve asthma 
control in more severe cases [6].
Allergen immunotherapy (AIT) is the only class of 
treatment for respiratory allergy that has the potential 
to change the course of the disease. Its immunologi-
cal mechanisms of action involve induction of allergen-
specific immune tolerance. AIT for allergic asthma is 
therefore a potential therapeutic option in appropriately 
selected patients with allergic asthma.
The European Academy of Allergy and Clinical 
Immunology (EAACI) is in the process of developing 
the EAACI Guidelines on Allergen Immunotherapy for 
Allergic Asthma. Guideline recommendations will be 
informed by formal evidence syntheses of the literature. 
This article is an overarching synthesis of the systematic 
review evidence on the effectiveness, cost-effectiveness 
and safety of AIT in the management of allergic asthma. 
It will be followed by a review of the primary studies.
Methods
A detailed description of our methods is available in the 
published systematic review protocol [7]. We therefore 
confine ourselves here to a summary of our methods.
Search strategy
Electronic literature searches were conducted to retrieve 
systematic reviews that have been conducted in relation 
to AIT for allergic asthma from the following electronic 
databases: Medline, Embase, Cochrane Library, HTA, EED, 
CINAHL, ISI Web of Science, TRIP, Current controlled tri-
als and Australian and New Zealand Clinical Trials registry.
A highly sensitive search strategy was developed, and 
validated study design filters were applied to retrieve arti-
cles pertaining to the use of AIT for allergic asthma from 
electronic bibliographic databases (“Appendix”). We used 
the systematic review filter developed at McMaster Uni-
versity Health Information Research Unit (HIRU) (http://
hiru.mcmaster.ca/hiru/HIRU_Hedges_MEDLINE_Strat-
egies.aspx#Reviews). Based on further abstract and full 
paper screening, all systematic reviews were identified 
and screened for inclusion. The searches were for arti-
cles published from inception of the databases up to 31st 
October 2015. No language restrictions were applied. All 
titles were uploaded into the systematic review software 
Distiller SR (Evidence Partners, Ottawa, Canada).
Eligibility criteria
We were interested in systematic reviews of randomized 
controlled trials (RCTs) in which AIT for different aller-
gens (e.g. pollens, mites, animal dander and cockroach) 
were administered through the subcutaneous (SCIT) or 
sublingual (SLIT) routes compared with placebo or any 
active comparator.
Participants of interest were patients of any age with 
a physician confirmed diagnosis of allergic asthma, plus 
evidence of clinically relevant allergic sensitization as 
assessed by an objective biomarker (e.g. skin prick test 
or specific-IgE), in combination with a history of asthma 
symptoms due to allergen exposure. Reviews that inves-
tigated participants with both asthma and rhinitis/rhi-
noconjuctivitis, but presented separate outcomes for the 
two conditions were also included.
The primary outcome of interest was the effective-
ness—both short-term and long-term, where long-term 
was defined as persistence of benefit after discontinua-
tion of treatment—of AIT as assessed by symptoms and/
or medication scores.
Secondary outcomes of interest included asthma con-
trol, asthma specific quality of life, exacerbations, lung 
function, environmental exposure chamber or bron-
chial allergen challenge, cost-effectiveness and safety as 
assessed by local and systemic reactions.
Selection procedures
Title and abstract screening was conducted indepen-
dently by two reviewers (SD and FS) and for those that 
appeared to meet the inclusion criteria full-texts were 
independently retrieved and screened (AK and FA). Any 
disagreements were resolved through discussion or, if 
necessary, arbitration by a third reviewer (SD).
Data extraction
Data were extracted independently in Distiller SR by 
two reviewers (FA and AK) using pre-defined criteria. 
Disagreements were resolved by discussion between the 
reviewers and where agreement could not be reached by 
arbitration with a third reviewer (SD).
Quality assessment
Independent quality assessment of all systematic reviews 
was undertaken by two reviewers (FA and AK) using 
the Critical Appraisal Skills Programme (CASP) tool 
for systematic reviews [8]. Disagreements were resolved 
through discussion; if agreement could not be reached a 
third reviewer (SD) arbitrated.
Synthesis of evidence
Abstracted data were included into descriptive tables 
that included information on search strategy, population 
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characteristics, study design, quality assessment, expo-
sure, outcomes and subgroup analyses. Because of mul-
tiple outcomes of this overview and since there is no 
consensus whether and how meta-analysis should be per-
formed from systematic reviews, we did not undertake 
meta-analysis.
Results
Characteristics of included systematic review
Our searches retrieved nine systematic reviews, five of 
which included meta-analyses (see Fig.  1). The key fea-
tures of these systematic reviews are summarized in 
Table 1.
The nine systematic reviews included 272 individual 
RCTs studying over 13,000 patients with asthma. Eight of 
the systematic reviews studied both children and adults 
[9–16]; whilst one focused on children only [17]. Two 
systematic reviews evaluated AIT for a single-allergen 
(i.e. house dust mite) [13, 17]. The remaining seven stud-
ied AIT for multiple allergens, these including animal 
dander, mold natural, pollens, modified allergens and 
latex [10–12, 14–16, 18]. Three systematic reviews evalu-
ated SCIT [10, 14, 17], four evaluated SLIT [11, 13, 15, 
16], and two examined a combination of SCIT and SLIT 
[12, 18].
The majority of the systematic reviews had primary 
outcomes which focused on asthma symptoms, medica-
tion usage, allergen-specific bronchial hyper-reactivity 
(BHR) and exacerbations with secondary outcomes of 
safety and disease specific quality of life (Table 1).
Quality assessment
Two reviews by Abramson et  al. and Normansell et  al. 
were judged to be at low risk of bias [10, 15]. The remain-
ing reviews were classified as being at moderate risk of 
bias (Table 2) [11–14, 16, 17].
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SCIT focused reviews
Asthma symptom scores
The strongest evidence for asthma symptom reduction 
was provided by the meta-analysis by Abramson et  al., 
which included 88 RCTs of moderate quality randomiz-
ing a total of 3459 asthma patients [10]. Meta-analysis 
demonstrated a significant improvement in asthma 
symptoms scores based on data from thirty-five trials: 
the estimated standardised mean difference (SMD) for all 
allergens combined was −0.59 (95% CI −0.83 to −0.35) 
for AIT versus placebo, but there was high heterogene-
ity between studies  (I2  =  73%). The authors concluded 
that it would have been necessary to treat three patients 
(NNT  =  3; 95% CI 3–5) to avoid one person’s asthma 
symptoms deteriorating. Significant improvement of 
symptoms was most likely with AIT to pollen (NNT = 3; 
95% CI 2–16); animal dander (NNT = 3; 95% CI 2–18) 
and other allergens such as molds, chemically modified 
allergoids or antigen–antibody complexes (NNT  =  3; 
95% CI 3–4). A smaller improvement was observed fol-
lowing HDM immunotherapy where six patients would 
need to be treated to avoid one deteriorating (NNT = 6; 
95% CI 4–16). Only one trial directly compared AIT to 
inhaled corticosteroids and this found that symptoms 
improved more rapidly on inhaled steroids than AIT [18].
A further three reviews undertook a qualitative syn-
thesis of the impact of AIT on asthma symptom scores. 
Erekosima et  al. [14] reported on 10 studies [19–28], 
including 628 participants, that evaluated SCIT for con-
trol of asthma symptoms (eight compared SCIT to pla-
cebo, one compared SCIT to pharmacotherapy, and 
one compared SCIT to no SCIT); 90% of these studies 
reported a greater improvement in the SCIT arm than in 
the comparator arm. All of these trials used a single aller-
gen: six were for HDM, one Cladosporitum, one timothy 
grass, one ragweed and one cat allergens. The review by 
Polzehl et al., which focused on the efficacy of SCIT with 
HDM extracts (Dermatophagides pteronyssinus or farina) 
in 442 adolescents and adults, reported that seven out of 
12 studies showed a significant improvement in asthma 
symptom scores when compared to placebo [17].
Kim et  al., using a narrative synthesis, reported evi-
dence to demonstrate that SCIT improved asthma symp-
toms compared with placebo or pharmacotherapy [18]. 
This was only true however when using a single allergen; 
when multiple allergens were used, this was not the case. 
This evidence was from moderate to high quality studies.
Asthma medication scores
The review by Abramson et al. pooled evidence from 21 
studies to show that AIT significantly decreased medica-
tion usage with an SMD for all allergens combined versus 
placebo of −0.53 (95% CI −0.80 to −0.27) with moderate 
between study heterogeneity  (I2  =  67%) [10]. Over-
all, it would have been necessary to treat four patients 
(NNT =  4; 95% CI 4–7) with AIT to avoid one patient 
requiring an increase in medication.
In Erekosima et al. [14], eight studies [18–22, 25, 29, 
30], all using single allergen AIT, including 592 patients, 
reported on medication scores [18]. Five out of eight 
studies demonstrated a greater reduction in medica-
tion use in the SCIT group than in the comparator arm 
and two of the studies did not report the direction of 
change. Polzehl et  al. [17] reported on asthma medi-
cation use in 10 studies: five of these showed a signifi-
cant decrease in medication requirement after therapy 
whereas the remaining five studies showed no signifi-
cant effect. Interestingly, no improvement was seen in 
four trials, which included patients with moderate-to-
severe asthma.
Kim et al. presented results from four studies using sin-
gle allergens which demonstrated that the SCIT group 
had a reduction in medication score greater than the 
control group [18]. A further study however reported the 
same scores for the treatment and placebo group.
Asthma control and exacerbations
No results were available for these outcomes.
Disease specific quality of life
Kim et al. reported quality of life outcomes in two SCIT 
studies [18]. Of these, a study of 50 patients with moder-
ate risk of bias showed a significant improvement in qual-
ity of life in both patients and their parents and the other, 
a study of 300 patients with high risk of bias, showed no 
difference in SCIT and control groups.
Lung function
In Abramson et  al., of the 88 included studies 20 pro-
vided results for lung function [10]. Data for peak expira-
tory flow (PEF) and forced expiratory volume in one 
second (FEV1) were meta-analyzed. The overall results 
were inconclusive regarding the impact of AIT on lung 
function when compared to placebo: SMD for PEF 0.14 
(95% CI −0.33 to 0.61) and SMD for FEV1 −0.32 (95% 
CI −0.96 to 0.31).with high between study heterogene-
ity  (I2 = 81% for PEF; and  I2 = 61% for FEV1) In seven 
studies reporting on lung function deterioration (simply 
as improved, worsened or the same), there was an overall 
trend implying lung function improvement after immu-
notherapy, but this did not reach statistical significance 
(RR 0.89; 95% CI 0.73–1.10).
In Erekosima et  al., 11 studies enrolling 873 partici-
pants reported that the impact on lung function was ‘var-
iable and inconsistent across studies’ (no further details 
provided) [14]. Polzehl et al., from nine studies, found no 
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significant changes in lung function between SCIT and 
placebo [17].
Environmental exposure chamber or bronchial allergen 
challenge
Three systematic reviews reported on bronchial aller-
gen challenge . Meta-analysis results of 18 studies from 
Abramson et  al. [10] showed that AIT reduced non-
specific BHR following challenges when compared to 
placebo: overall SMD of −0.35 (95% CI −0.59 to −0.11). 
These effects were significant for methacholine: SMD of 
−0.25 (95% CI −0.51 to 0.00) and acetylcholine: SMD 
−1.29 (95% CI −2.28 to −0.31), but not for histamine: 
SMD −0.55 (95% CI −1.37 to 0.28) or cold air: SMD 
−0.52 (95% CI −1.31 to 0.26). Non-specific BHR was 
reported as increased, reduced or unchanged in five stud-
ies with an estimated RR for increased non-specific BHR 
of 0.48 (95% CI 0.33–0.72) favoring AIT.
In Erekosima et  al., 13 studies reported on non-spe-
cific bronchial provocation tests on 568 participants in 
total [14]. Five out of 13 studies demonstrated greater 
improvement in the AIT group than the comparator. 
In Polzehl et  al., two out of three studies showed sig-
nificant improvement to methacholine challenge after 
12–18 months [17].
Meta-analysis of 19 trials in the systematic review by 
Abramson et al. showed a significant reduction in aller-
gen specific BHR following immunotherapy compared to 
placebo: mite SMD −0.98 (95% CI −1.39 to −0.58), pol-
len SMD −0.55 (95% CI −0.84 to −0.27), animal dander 
SMD −0.61 (95% CI −0.95 to −0.27), other allergens 
SMD −0.18 (95% CI −0.70 to 0.33) and overall SMD 
−0.61 (95% CI −0.79 to −0.43) [10]. Allergen specific 
BHR was reported as increased, reduced or unchanged 
in 16 studies with an estimated RR for increased allergen 
specific BHR of 0.51 (95% CI 0.41–0.63) favoring AIT.
In Erekosima et  al., eight out of 11 studies demon-
strated statistically significant improvement in the SCIT 
group that the comparator [14]. Finally, in Polzehl et al., 
three out of three studies showed significant improve-
ment in the immunotherapy group [17].
Safety
Abramson and colleagues in their systematic review 
reported on both local and systemic adverse reactions 
[10]. The pooled relative risk for local adverse reac-
tions, as it was reported in ten studies, was 1.4 (95% CI 
0.97–2.02) and homogenous  (I2  =  0.0%). So, if sixteen 
patients were treated with immunotherapy, one would 
be expected to develop a local reaction. Systemic adverse 
reactions defined as anaphylaxis, asthma, rhinitis, urti-
caria or any combination of these were reported by 32 
studies. The pooled relative risk for systemic reactions of 
any severity was 2.45 (95% CI 1.91–3.13) and relatively 
homogenous  (I2  =  27%). They concluded that if nine 
patients were treated with immunotherapy, one would be 
expected to develop a systemic reaction.
Erekosima et al. reported data on safety from 35 trials 
[14]. Local reactions were reported in 11 studies, these 
showing that 71/346 (20.5%) patients in the SCIT arm 
experienced local reactions compared to 1/7 (14.3%) in 
the comparator arm. General reactions were reported 
in 14 studies, according to which 190/624 (30.4%) in the 
SCIT arm experienced general reactions, compared to 
52/217 (24.0%) in the comparator arm. Finally anaphylac-
tic reactions were reported in four studies and all events 
were concerning patients on immunotherapy (13/205 
(6.3%) patients).The other study that reported on this 
outcome was Polzehl et  al., which found that seven out 
of the thirteen studies showed no severe adverse events 
[17]. Four studies however, reported systemic adverse 
effects.
Kim et  al. reported from 10 SCIT studies local reac-
tions occurring at the injection site in both the treatment 
and placebo groups [18]. In terms of systemic reactions, 
bronchospasm occurred in 1–30% of patients and general 
systemic reactions in 3–34% of patients.
SLIT focused reviews
Asthma symptom scores
Evidence from the meta-analysis by Calamita et  al. [11] 
which included 25 RCTs (19 double-blind and six open) 
showed a non-significant reduction in asthma symptoms 
in the SLIT arm compared to placebo: the SMD from 
meta-analysis of nine studies (enrolling 303 patients) t 
was −0.38 (95% CI −0.79 to 0.03).
The systematic review by Compalati et  al., which 
included nine double-blind placebo controlled RCTs, 
found a significant reduction in symptom scores: SMD 
−0.95 (95% CI −1.74 to −0.15) compared to the placebo 
group; there was high heterogeneity  (I2 = 92%) [13].
Normansell et al. found symptom scores in 42 studies, 
but only 17 presented these in a numerical fashion [15]. 
Of these studies, five showed no statistical significant dif-
ference between groups, nine studies reported statisti-
cally significant reductions in the SLIT group compared 
with the placebo group; two studies showed a small 
improvement and one study reported a marked reduction 
in symptoms during cat exposure for the SLIT group.
Tao et al. [16] which included 16 double-blind placebo 
controlled RCTs demonstrated that there was a significant 
reduction in patients symptom scores in the SLIT group 
compared to the placebo group: pooled SMD of −0.74 
(95% CI −1.26 to −0.22), with significant between study 
heterogeneity  (I2 = 91%). Subgroup analysis according to 
age showed that SMD was −0.87 (95% CI −1.54 to −0.21) 
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in children and −0.40 (95% CI −1.36 to −0.25) in adults. 
Subgroup analysis by allergen showed a beneficial effect 
in the context of mite immunotherapy: SMD −0.97 (95% 
CI −1.69 to −0.25), but not pollen immunotherapy: SMD 
−0.29 (95% CI −0.96 to 0.38). Finally, subgroup analysis 
according to treatment duration showed that SMD was 
−0.96 (95% CI −1.69 to −0.22) for treatment less than 
12  months whereas SMD was −0.60 (95% CI −1.30 to 
0.10) for greater than 12 months of treatment.
Kim et  al. using a narrative synthesis indicated that 
there was evidence to demonstrate that SLIT improved 
asthma symptoms compared with placebo or pharmaco-
therapy [18].
Asthma medications scores
Meta-analysis results of six studies (with 254 patients) 
from Calamita et  al. showed that there was a tendency 
towards improved medication scores favored by SLIT, but 
this was not conclusively shown: SMD of −0.91 (95% CI 
−1.94 to 0.12) with significant between studies heteroge-
neity  (I2 = 91.8%) [11]. The results from Compalati et al., 
from seven studies enrolling 220 patients looking at dust 
mite allergen, however presented a significant (P = 0.02) 
reduction in rescue medication use: SMD −1.48 (95% CI 
−2.70 to −0.26) but significant heterogeneity  (I2 = 96%).
Subgroup analysis according to age, showed a signifi-
cant reduction in children (SMD −1.86; 95% CI −3.34 to 
−0.38) but not in adults (SMD 0.23; 95% CI −0.33 to 0.78) 
[13]. Normansell et  al. reported this outcome numeri-
cally in twelve studies, five of which reported favorably 
for the SLIT group and seven of which showed no statis-
tically significant difference between groups [15]. Results 
from Tao et al., indicated that medication score was sig-
nificantly (P = 0.02) reduced in the SLIT group compared 
to their comparators (SMD of −0.78; 95% CI −1.45 to 
−0.11), but there was significant heterogeneity  (I2 = 93%) 
[16]. They also looked at children and adults separately 
and found that whereas in children there was a statisti-
cally significant reduction in medication score with SLIT 
(SMD −1.1; 95% CI −2.06 to −0.14, P =  0.03) this was 
not the case for adults (SMD −0.00; 95% CI −0.36 to 0.36; 
P  =  0.99). They also indicated that prolonged duration 
of treatment did not have any additive beneficial effect: 
SMD for less than 12  month treatment was −0.98 (95% 
CI −2.14 to 0.19) and SMD for more than 12 months of 
treatment was −0.51 (95% CI −1.17 to 0.16).
Kim et al. included nine studies which reported on this 
outcome in relation to asthma: seven for HDM showed a 
significant improvement compared to placebo [18].
Asthma control
Calamita et al. found that seven studies had reported on 
general asthma control, combining asthmatic symptoms, 
need for symptom relief medication, respiratory func-
tion test and lung hyper-reactivity, and found a sig-
nificant improvement for AIT over placebo: RD −0.27 
(95% CI −0.33 to −0.21) and RR 0.48 (95% CI 0.4–0.57). 
There was little heterogeneity between these studies 
 (I2 = 36.3%) [11].
Tao et  al. reported that two studies looked at ‘global 
improvement’, considering symptom remission, medica-
tion use and lung function, but they failed to identify any 
significant improvement (RR 3.31; 95% CI 0.25–44.44) 
[16].
Kim et  al. reported two studies which looked at gen-
eral asthma control [18]. One study found that after six 
months of SLIT to HDM compared to placebo, classifi-
cation of asthma in the treatment group changed from 
‘mild-moderate persistent to mild intermittent’. The sec-
ond study however concluded that after three years of 
SLIT treatment there was no difference in the number of 
children with mild intermittent asthma when compared 
to the placebo group.
Exacerbations
Normansell et  al. reported on this outcome with data 
from one small study, enrolling 43 patients, which was 
assessed to be at high risk of bias [15]. It reported no 
exacerbations requiring emergency department attend-
ance or hospital admission during the (four week) treat-
ment period or the follow up period (5–6 weeks) in either 
the SLIT or placebo arms.
Disease specific quality of life
Normansell et  al. reported data on this outcome from 
five of the included studies, but no meta-analysis could 
be performed [15]. Results from these five studies were 
variable, this possibly in part because a number of tools 
had been used not all of which were specific to asthma. 
Overall, two studies found no significant difference in dis-
ease specific quality of life scores, two found a significant 
improvement, and the fifth was equivocal.
Kim et al. reported quality of life outcomes in only two 
SLIT studies, both showed no improvement in quality of 
life [18].
Lung function
Calamita et  al. indicated that treatment by SLIT failed 
to show a significant improvement in FEV1%: SMD of 
1.48 (95% CI 0.13–2.82) among 144 patient in four of the 
studies that investigated this outcome. FEF 25–75% also 
did not achieve statistical significance: SMD 1.06 (95% CI 
0.40–1.72) among 42 patients in two studies [11]. Simi-
larly, Tao et al. found, from five studies, no improvement 
in FEV1% pooled SMD of 0.49 (95% CI −0.36 to 1.34; 
P = 0.26) in the SLIT group [16].
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Environmental exposure chamber or bronchial allergen 
challenge
Calamata et  al. reported that there was no significant 
improvement in bronchial provocation tests in the SLIT 
group, but no data were presented [11]. Normansell et al. 
found 11 studies which used the methacholine provo-
cation test. Data from four of these trials were pooled; 
meta-analysis failed to show any evidence of benefit: 
SMD 0.69, 95% CI −0.04 to 1.43, with a high level of het-
erogeneity  (I2 = 76%) [15].
Safety
Calamita et  al. reported adverse effects reported in 20 
studies enrolling 1501 patients. Only mild adverse events 
were seen, the majority resolving without the need for 
treatment [11]. The relative risk of adverse effects was 
1.83 (95% CI 1.40–2.40) and RD was 0.07 (95% CI 0.04–
0.10) with a number needed to harm (NNH) for AIT of 
14.3.
Normansell et al., from 22 RCTs, reported that serious 
adverse events were uncommon, occurring in 1 in 100 
patients using SLIT (RD 0.001, 95% CI −0.008 to 0.010; 
moderate-quality evidence) [15]. When they looked at 
all AEs, however, they showed an increase of AEs in the 
SLIT group compared to the placebo with an OR of 1.70 
(95% CI 1.21–2.38). Most of these AEs were however 
mild.
Tao et al., also concluded that the AEs were mild such 
as mouth and throat itchiness, redness and swelling [16]. 
Pooled data analysis through meta-analysis resulted in a 
significant risk in a RR 2.23 (95% CI 1.17–4.2; P = 0.01) 
with high level of heterogeneity  (I2  =  75%). Kim et  al. 
found in 12 SLIT studies a rate of local reactions from 
0.2–50% in the treatment group but 6–25% in the pla-
cebo group [18]. Systemic reactions were common, but 
not life threatening and occurred in both treatment and 
placebo groups.
Reviews including both SCIT and SLIT studies
Two systematic reviews examined the effect of SLIT ver-
sus SCIT on asthma. Kim et al. looked solely at children 
and included 27 trials: 12 SLIT and 12 SCIT, the results 
of which have been discussed above under the appropri-
ate headings; there were a further three trials comparing 
the two treatment routes [18]. Chelladurai et al. looked at 
a head-to-head comparison of the two routes of adminis-
tration [12].
Asthma symptom score
Kim et al., using a narrative synthesis, found that in the 
studies that looked at SLIT versus SCIT there was no 
conclusive evidence to favor one route of administration 
over the other in terms of symptom scores [18].
A comparison between SCIT and SLIT was under-
taken in the review by Chelladurai et al., which included 
four studies of asthma patients all using HDM immuno-
therapy [12]. They demonstrated a greater reduction in 
asthma symptoms from three studies with SCIT com-
pared to SLIT, whereas one study showed greater reduc-
tion in symptoms with SLIT. All of these studies were 
judged to be of moderate quality.
Asthma medication score
Kim et al. presented results from three studies of HDM 
immunotherapy directly comparing SLIT with SCIT, but 
there was no conclusive evidence to favor one route of 
administration over the other in terms of reducing medi-
cation scores. Two studies were described as favoring 
SCIT over SLIT for improving medication use, whereas 
one study favored SLIT.
Chelladurai et  al., found that when comparing the 
HDM studies two studies favored SCIT in reducing med-
ications usage while two favored SLIT [12].
Asthma control
No results were available for this outcome.
Disease specific quality of life
No results were available for these outcomes.
Lung function and environmental exposure chamber or 
bronchial allergen challenge
No results were available for these outcomes.
Safety
In Kim et  al. among the three studies (including 135 
children) that examined SCIT versus SLIT, local reac-
tions were reported in three patients receiving SLIT and 
in three patients receiving SCIT. No systemic reactions 
were reported in patients receiving SLIT. Among the 
patients that received SCIT, four experienced systemic 
reactions, including one anaphylaxis event (anaphylaxis 
was defined as flushing, wheezing and dyspnea requiring 
adrenaline) [18].
In the comparison between SCIT and SLIT, Chella-
durai et al. indicated that eight studies reported on AEs, 
however due to the heterogeneity data could not be 
pooled [12]. Local reactions occurred both in SCIT and 
SLIT with no fatalities; however SLIT was associated 
with an increased frequency of local reactions (7–56%) 
compared with SCIT (20%). The only episode of anaphy-
laxis was reported in one study in a child treated with 
SCIT.
Health economic outcomes
No results were available for this outcome.
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Discussion
Statement of principal findings
We found clear evidence that AIT administered by the 
SCIT route is effective in improving medication and 
symptom scores. The evidence in relation to the effective-
ness of SLIT for these outcomes was more mixed. It is 
interesting to note however, that the review by Compalati 
et al. [12] which looked only at HDM AIT shows signifi-
cant reductions in both symptom and medication scores 
for asthma compared to the review by Calamita et  al. 
[11] which looks at a number of allergens which shows 
no significant reduction when considering the same out-
comes. In terms of lung function no positive result could 
be concluded for either SCIT or SLIT. With regards to 
BHR, some of the studies showed an improvement in the 
SCIT group, but no clear conclusions could be drawn 
and no improvement in the SLIT group could be dem-
onstrated for this outcome. There was considerable vari-
ation in results dependent upon which allergen was used 
and whether multiple or single allergens were adminis-
tered with single allergen AIT faring more favorably. The 
two systematic reviews by Kim et al. [18] and Chelladurai 
et al. [12] which compared the two routes of administra-
tion could not conclusively show any difference between 
the effectiveness of SLIT and SCIT. Furthermore, it was 
difficult to compare results from these two reviews due 
to the heterogeneity between them including the fact 
that one was focused on the pediatric population only 
whilst the other looked at both adults and children. Fur-
thermore, although they both looked at AIT for HDM, 
they also looked at different allergens with one concen-
trating on tree mix and the other pollens. Across all of 
the reviews, there was considerable variation in results 
dependent upon which allergen was used and whether 
multiple or single allergens were administered.
Safety is a prime concern with any treatment and the 
safety profile of SLIT compares more favorably to SCIT 
particularly in relation to the risk of systemic reactions. 
However, no fatalities were reported with either route of 
administration.
There were very few studies which considered and 
reported on disease specific quality of life as a study out-
come. As a result due to the paucity of data present no 
conclusions can be drawn. This is therefore clearly an 
area that warrants further enquiry. Studies that consid-
ered this outcome used many different tools to assess 
quality of life some of which were not disease specific. 
This is another area where uniformity of reporting is 
urgently required.
Strengths and limitations
We believe this is the first such synthesis of data from 
systematic reviews on AIT that has been undertaken. We 
used standard systematic overview techniques, which 
will have helped to minimize the risk of bias.
There are nonetheless some limitations of systematic 
overviews which should be considered when interpreting 
the results. First is in relation to the quality of studies that 
were included in the individual systematic reviews, many 
of which were at moderate or high risk of bias. Second is 
the wide variety of studies included within these system-
atic reviews, the majority of which are dated. They included 
patients with varying severities of asthma, allergies and 
treatment with single or multiple allergens and with treat-
ment regimens of varying length and follow-up. Further-
more, there was no standardization of outcomes measured 
and even when outcomes overlapped there was still no 
standardization of measurements taken. This heterogene-
ity of studies may in part account for the varied results that 
were seen. Finally, meta-analysis was mainly confined in 
the studies that investigated SLIT rather than SCIT.
Conclusions
This systematic overview has identified a substantial evi-
dence base investigating the effectiveness and safety of 
AIT for allergic asthma, this showing that overall this 
treatment modality has the potential to improve medi-
cation and symptom scores. There was some indirect 
evidence to suggest that the effectiveness of SCIT may 
be superior to SLIT, but that the safety profile of SLIT is 
superior in relation to systemic AEs. We found no evi-
dence in relation to cost-effectiveness considerations and 
equivocal and little or no evidence in relation to many of 
our secondary effectiveness outcomes of interest. A fol-
low-on, more up-to-date evidence synthesis of primary 
studies may help to provide further clarity on the effec-
tiveness, safety and cost-effectiveness of AIT.
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Appendix
Search strategy 1
(MEDLINE, EMBASE)
 1. exp asthma/
 2. asthma.mp.
 3. asthmatic children.mp.
 4. acute asthmatic attack.mp.
 5. asthma control.mp.
 6. asthma exacerbations.mp.
 7. wheez*.mp.
 8. respiratory hypersensitivity/
 9. bronchial disorder.mp.
 10. hyper-responsiveness wheez*.mp.
 11. lung function.mp.
 12. ventilatory function.mp.
 13. FEV.mp.
 14. FEF.mp.
 15. FVC.mp.
 16. PEF.mp.
 17. bronchial hyperreactivity.mp.
 18. airway hyperreactivity.mp.
 19. bronchial responsiveness.mp.
 20. airway responsiveness.mp.
 21. or/1-20
 22. exp Desensitization, Immunologic/
 23. exp Immunotherapy/
 24. desensiti?ation.mp.
 25. (immunotherapy or allergen immunotherapy or oral 
immunotherapy).mp.
 26. subcutaneous immunotherapy.mp.
 27. sublingual immunotherapy.mp.
 28. specific immunotherapy.mp.
 29. Or/22-28
 30. exp Intervention Studies/
 31. intervention studies.mp.
 32. exp Clinical Trial/
 33. (trial or clinical trial).mp.
 34. Exp Randomized Controlled Trial/
 35. randomi?ed controlled trial.mp.
 36. exp Placebos/
 37. placebos.mp.
 38. exp Random allocation/
 39. random allocation.mp.
 40. random*.mp.
 41. exp Double-blind method/
 42. double-blind method.mp.
 43. double-blind design.mp.
 44. exp Single-blind method/
 45. single-blind method.mp.
 46. single-blind design.mp.
 47. triple-blind method.mp.
 48. search:.tw.
 49. review.pt.
 50. systematic review.tw.
 51. meta analysis.mp,pt.
 52. case series.mp.
 53. (case$ and series).tw.
 54. cost:.mp.
 55. cost effective:.mp.
 56. cost utility:.mp.
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 57. exp Health Care Costs/
 58. (costs and costs analysis).mp.
 59. economic evaluation*.mp.
 60. ((cost effective* adj1 analys*) or cost minimi?ation 
analys* or cost benefit analys* or cost utility analys* 
or cost consequence analys* or finances).mp.
 61. Or/30-60
 62. 21 and 29 and 61
Search strategy 2
(Cochrane library, HTA, EED, CINAHL, ISI Web of 
Science, TRIP)
(Asthma or acute asthmatic attack or wheez* or res-
piratory hypersensitivity or bronchial disorder or hyper-
responsiveness wheez* or lung function or ventilatory 
function or bronchial hyperreactivity or airway hyperreac-
tivity or bronchial responsiveness or airway responsiveness)
AND
(Immunologic, desensiti* or immunotherapy or oral 
immunotherapy or allergen immunotherapy or specific 
immunotherapy or subcutaneous immunotherapy or 
sublingual immunotherapy)
AND
(Intervention stud* or experimental stud* or trial or 
clinical trial* or randomi* controlled trial or random allo-
cation or single blind method or double blind method 
or triple blind method or random* or systematic review 
or meta-analysis or case series or economic evaluation* 
or cost effective* analys* or cost minimi?ation analys* or 
cost benefit analys* or cost utility analys* or cost conse-
quence analys* or finances)
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